Tarsus Pharmaceuticals, Inc.

Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to TARSA's second quarter 2025 earnings conference call. As a reminder, this call is being recorded. At this time, I would like to turn the call over to David Nakasane, head of investor relations, to lead off the call. David, you may begin.

Thank you. Before we begin, I encourage everyone to visit the investor section of the TARCIS website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Madawala, our Chief Commercial Officer, and Jeff Farrell, our Chief Financial Officer and Chief Strategy Officer. I'd like to draw your attention to slide three, which contains our forward-looking statements. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional details. With that, I will turn the call over to Bobby.

Thank you, Dave. Good afternoon, everyone, and thank you for joining us. We are approaching the two-year anniversary of the launch of Xtembe. the first and only FDA-approved treatment for demodex blepharitis. In that time, we've established a new category in eye care and executed one of the most successful launches ever in the prescription eye drop market. This success is more than a milestone. It's powerful validation of our scientific innovation, strategy, and leadership, and a clear signal that our vision of becoming the next leader in eye care isn't just aspirational, It's already taking shape with measurable impact. In Q2, we delivered record-breaking results of more than $100 million in net sales and approximately 91,000 bottles dispensed to patients in need. This quarter-over-quarter growth is even more impressive when you consider we are primarily a new prescription or NRX business and do not yet benefit from meaningful refills at this stage of the launch. These impressive Q2 results reflect continued momentum in physician education and adoption, strong high-quality access, and increasing patient demand, underscoring the meaningful value Xtemvi is delivering to those living with demonex blepharitis. They also reflect the early impact of our direct consumer campaign, which is driving prescription volumes. With an estimated 25 million people in the U.S. living with demonyx blepharitis, or DB, this campaign is proving to be a powerful catalyst in opening new conversations, changing physician behavior, and encouraging patients to take action, all of which is making Xdemvi a household name. That momentum is echoed in real-time feedback from the field, reinforcing my bullishness on this investment and its potential to provide even greater access to the DB market. Coupled with this early DTC success, our continued focus on education, broad payer access, and the outstanding execution by our sales force strengthens our conviction that the peak potential opportunity for Xtemvi is even greater than we originally envisioned. This growing momentum doesn't stop with Xtemvi. It also extends across our robust and differentiated pipelines. With a proven blueprint for success that includes an exceptional management team, a distinctive approach to innovation, and Extenvi as a compelling proof point, we are well positioned to create and lead entirely new categories across eye care. One of our most promising programs advancing through development is TPO4 for ocularization, or OR. OR is yet another uncharted therapeutic space, and we're applying the same discipline strategy that propelled Xtemvi's success, deep scientific insight, commercial acumen, and a relentless focus on execution. In summary, the opportunity ahead is substantial and accelerating, and we believe Xtemvi's peak potential is even greater than we initially projected. Fueled by growth drivers across commercial execution and clinical innovation, and supported by a solid financial foundation, we're not just positioned to succeed, we're poised to potentially leave the next era of eye care. Before I pass the call to Aziz, I want to sincerely thank the entire Tarsus team for their dedication, passion, and relentless focus on creating new categories in medicine. You have been fundamental to everything we've achieved and everything we're building towards. With that, I'll turn the call over to Aziz.